Drugs / Kukoamine B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03237728 | Jul 2017 → Sep 2019 | infectious disease with sepsis | Tianjin Chasesun Pharmaceutical Co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT02690961 | Mar → Jun 2016 | — | Tianjin Chasesun Pharmaceutical Co., LTD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | kukoamine B | “PURPOSE: To evaluate the safety, tolerability, pharmacokinetics, and efficacy of kukoamine B (KB), an alkaloid compound with high affinity for both lipopolysaccharide (LPS) and...” PMID 37116228 ↗ Apr 2023 |
| Modality | Small molecule | “kukoamine B (KB), an alkaloid compound” PMID 37116228 ↗ Apr 2023 |
| Route | Intravenous | “intravenous(IV) drip for 1 hour” NCT02690961 ↗ |